Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140k into hematopoietic stem cells

Michael Jansen, Ursula R. Sorg, Susanne Ragg, Michael Flasshove, Siegfried Seeber, David A. Williams, Thomas Moritz

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The overexpression of mutant forms of O6 -methylguanine-DNA-methyltransferase (MGMT), resistant to the MGMT inhibitor O6-benzylguanine (BG), protects hematopoietic cells from the toxicity of combined BG plus O6-alkylating agent chemotherapy. To evaluate the feasibility of this approach for clinically relevant O6-alkylating agents, combined therapy with BG and two chloroethylnitrosourea-type drugs, ACNU or BCNU, or the triazene derivative temozolomide (TMZ) was investigated in a murine bone marrow transplant model allowing transgenic expression of the highly BG-resistant MGMTP14OK mutant. Whereas 20/20 control animals transplanted with nontransduced cells died of progressive myelosuppression during therapy, nearly all animals transplanted with MGMTP14OK-transduced cells survived treatment with BG/ACNU (12/15), BG/TMZ (10/10), or BG/BCNU (5/5). In surviving animals, hematological parameters improved during chemotherapy and pretreatment levels were reestablished during or shortly after therapy. All animals showed enrichment of transgenic granulocytes (range: 15- to 101-fold) and lymphocytes (range: 16- to 55-fold) in peripheral blood, bone marrow, and spleen. No significant differences were observed between individual treatment groups. Serial transplants demonstrated protection in secondary recipients and confirmed the transduction of transplantable stem cells. Thus, these data demonstrate efficient protection from hematotoxicity and substantial enrichment of transgenic cells following MGMTP14OK gene transfer and treatment with different O6-alkylating drugs.

Original languageEnglish (US)
Pages (from-to)737-746
Number of pages10
JournalCancer Gene Therapy
Volume9
Issue number9
DOIs
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
temozolomide
Nimustine
Genes
Carmustine
Alkylating Agents
Methyltransferases
Therapeutics
Triazenes
Bone Marrow
Transplants
Drug Therapy
DNA
Granulocytes
Pharmaceutical Preparations
Stem Cells
Spleen
Lymphocytes

Keywords

  • Chloroethylnitrosoureas
  • DNA repair
  • Gene therapy
  • O-methylguanine-DNA-methyltransferase
  • Retroviral vectors
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140k into hematopoietic stem cells. / Jansen, Michael; Sorg, Ursula R.; Ragg, Susanne; Flasshove, Michael; Seeber, Siegfried; Williams, David A.; Moritz, Thomas.

In: Cancer Gene Therapy, Vol. 9, No. 9, 09.2002, p. 737-746.

Research output: Contribution to journalArticle

Jansen, Michael ; Sorg, Ursula R. ; Ragg, Susanne ; Flasshove, Michael ; Seeber, Siegfried ; Williams, David A. ; Moritz, Thomas. / Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140k into hematopoietic stem cells. In: Cancer Gene Therapy. 2002 ; Vol. 9, No. 9. pp. 737-746.
@article{e0846e3bdadd4f37910dac91649d33ea,
title = "Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140k into hematopoietic stem cells",
abstract = "The overexpression of mutant forms of O6 -methylguanine-DNA-methyltransferase (MGMT), resistant to the MGMT inhibitor O6-benzylguanine (BG), protects hematopoietic cells from the toxicity of combined BG plus O6-alkylating agent chemotherapy. To evaluate the feasibility of this approach for clinically relevant O6-alkylating agents, combined therapy with BG and two chloroethylnitrosourea-type drugs, ACNU or BCNU, or the triazene derivative temozolomide (TMZ) was investigated in a murine bone marrow transplant model allowing transgenic expression of the highly BG-resistant MGMTP14OK mutant. Whereas 20/20 control animals transplanted with nontransduced cells died of progressive myelosuppression during therapy, nearly all animals transplanted with MGMTP14OK-transduced cells survived treatment with BG/ACNU (12/15), BG/TMZ (10/10), or BG/BCNU (5/5). In surviving animals, hematological parameters improved during chemotherapy and pretreatment levels were reestablished during or shortly after therapy. All animals showed enrichment of transgenic granulocytes (range: 15- to 101-fold) and lymphocytes (range: 16- to 55-fold) in peripheral blood, bone marrow, and spleen. No significant differences were observed between individual treatment groups. Serial transplants demonstrated protection in secondary recipients and confirmed the transduction of transplantable stem cells. Thus, these data demonstrate efficient protection from hematotoxicity and substantial enrichment of transgenic cells following MGMTP14OK gene transfer and treatment with different O6-alkylating drugs.",
keywords = "Chloroethylnitrosoureas, DNA repair, Gene therapy, O-methylguanine-DNA-methyltransferase, Retroviral vectors, Temozolomide",
author = "Michael Jansen and Sorg, {Ursula R.} and Susanne Ragg and Michael Flasshove and Siegfried Seeber and Williams, {David A.} and Thomas Moritz",
year = "2002",
month = "9",
doi = "10.1038/sj.cgt.7700490",
language = "English (US)",
volume = "9",
pages = "737--746",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140k into hematopoietic stem cells

AU - Jansen, Michael

AU - Sorg, Ursula R.

AU - Ragg, Susanne

AU - Flasshove, Michael

AU - Seeber, Siegfried

AU - Williams, David A.

AU - Moritz, Thomas

PY - 2002/9

Y1 - 2002/9

N2 - The overexpression of mutant forms of O6 -methylguanine-DNA-methyltransferase (MGMT), resistant to the MGMT inhibitor O6-benzylguanine (BG), protects hematopoietic cells from the toxicity of combined BG plus O6-alkylating agent chemotherapy. To evaluate the feasibility of this approach for clinically relevant O6-alkylating agents, combined therapy with BG and two chloroethylnitrosourea-type drugs, ACNU or BCNU, or the triazene derivative temozolomide (TMZ) was investigated in a murine bone marrow transplant model allowing transgenic expression of the highly BG-resistant MGMTP14OK mutant. Whereas 20/20 control animals transplanted with nontransduced cells died of progressive myelosuppression during therapy, nearly all animals transplanted with MGMTP14OK-transduced cells survived treatment with BG/ACNU (12/15), BG/TMZ (10/10), or BG/BCNU (5/5). In surviving animals, hematological parameters improved during chemotherapy and pretreatment levels were reestablished during or shortly after therapy. All animals showed enrichment of transgenic granulocytes (range: 15- to 101-fold) and lymphocytes (range: 16- to 55-fold) in peripheral blood, bone marrow, and spleen. No significant differences were observed between individual treatment groups. Serial transplants demonstrated protection in secondary recipients and confirmed the transduction of transplantable stem cells. Thus, these data demonstrate efficient protection from hematotoxicity and substantial enrichment of transgenic cells following MGMTP14OK gene transfer and treatment with different O6-alkylating drugs.

AB - The overexpression of mutant forms of O6 -methylguanine-DNA-methyltransferase (MGMT), resistant to the MGMT inhibitor O6-benzylguanine (BG), protects hematopoietic cells from the toxicity of combined BG plus O6-alkylating agent chemotherapy. To evaluate the feasibility of this approach for clinically relevant O6-alkylating agents, combined therapy with BG and two chloroethylnitrosourea-type drugs, ACNU or BCNU, or the triazene derivative temozolomide (TMZ) was investigated in a murine bone marrow transplant model allowing transgenic expression of the highly BG-resistant MGMTP14OK mutant. Whereas 20/20 control animals transplanted with nontransduced cells died of progressive myelosuppression during therapy, nearly all animals transplanted with MGMTP14OK-transduced cells survived treatment with BG/ACNU (12/15), BG/TMZ (10/10), or BG/BCNU (5/5). In surviving animals, hematological parameters improved during chemotherapy and pretreatment levels were reestablished during or shortly after therapy. All animals showed enrichment of transgenic granulocytes (range: 15- to 101-fold) and lymphocytes (range: 16- to 55-fold) in peripheral blood, bone marrow, and spleen. No significant differences were observed between individual treatment groups. Serial transplants demonstrated protection in secondary recipients and confirmed the transduction of transplantable stem cells. Thus, these data demonstrate efficient protection from hematotoxicity and substantial enrichment of transgenic cells following MGMTP14OK gene transfer and treatment with different O6-alkylating drugs.

KW - Chloroethylnitrosoureas

KW - DNA repair

KW - Gene therapy

KW - O-methylguanine-DNA-methyltransferase

KW - Retroviral vectors

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=0036708229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036708229&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700490

DO - 10.1038/sj.cgt.7700490

M3 - Article

C2 - 12189523

AN - SCOPUS:0036708229

VL - 9

SP - 737

EP - 746

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 9

ER -